<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04367948</url>
  </required_header>
  <id_info>
    <org_study_id>XW-FAPI-001</org_study_id>
    <nct_id>NCT04367948</nct_id>
  </id_info>
  <brief_title>Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma</brief_title>
  <official_title>Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the normal physiological distribution of positron nuclide labeled NOTA-F API in
      human body and its detection efficiency for lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects first undergo an 18F-FDG test, followed by 68Ga-NOTA-FAPI04 or 18F-NOTA-FAPI04 test
      in groups.Investigate the standardized uptake value(SUV) of 68Ga/ 18F-NOTA-FAPI04 for the
      target lesion, the ratio of the standardized uptake value(SUVR) of 68Ga/ 18F-NOTA-FAPI04 for
      the target lesion within each time window to that of the normal corresponding tissue.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUV</measure>
    <time_frame>60 days</time_frame>
    <description>Standardized uptake value of 68Ga/ 18f-nota-fapi04 for target lesion of subject or suspected tumor in each time point window (SUV)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SUVR</measure>
    <time_frame>60 days</time_frame>
    <description>the ratio of the standardized uptake value(SUVR) of 68Ga/ 18f-nota-fapi04 for the target lesion or suspected tumor lesion within each time window to that of the normal tissue corresponding to the tumor lesion or suspected tumor lesion to the standardized uptake value of 68Ga/ 18f-nota-fapi04</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Tumor, Solid</condition>
  <condition>Positron-Emission Tomography</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>68Ga-NOTA-FAPI04</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18F-NOTA-FAPI04</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F-FDG and 68Ga-NOTA-FAPI04 PET/CT</intervention_name>
    <description>Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time</description>
    <arm_group_label>68Ga-NOTA-FAPI04</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F-FDG and 18F-NOTA-FAPI04 PET/CT</intervention_name>
    <description>Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time</description>
    <arm_group_label>18F-NOTA-FAPI04</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG score 0 or 1

          -  subjects with lymphoma or suspected tumor subjects who have recently (within 2 months)
             planned to receive pathological biopsy or tumor surgery

          -  expected survival ≥12 weeks

          -  blood routine, liver and kidney function meet the following criteria: blood routine:
             WBC≥4.0×109L or neutrophils ≥1.5×109L, PLT≥100×109/L, Hb≥90g/L;PT and APTT ULN 1.5 or
             less;Liver and kidney function: t-bil ≤1.5×ULT(upper limit of normal value),
             ALT/AST≤2.5ULN or ≤5×ULT(subjects with liver metastasis), ALP≤2.5ULN(ALP≤ 4.5ULN if
             there is bone metastasis or liver metastasis);BUN 1.5 x or less ULT, SCr 1.5 x or less
             ULT

          -  at least one measurable target lesion according to RECIST1.1

          -  women must use effective contraception during the study period and for 6 months after
             the end of the study (effective contraception means sterilization, hormone devices,
             condoms, contraceptives/pills, abstinence or vasectomy by a partner, etc.);Men should
             consent to subjects who must use contraception during the study period and for 6
             months after the end of the study period

          -  able to understand and sign the informed consent voluntarily, with good compliance.

        Exclusion Criteria:

          -  severe abnormalities of liver and kidney function;

          -  women preparing for pregnancy, pregnancy and lactation;

          -  cannot lie supine for half an hour;

          -  refuse to join the clinical researcher;

          -  suffering from claustrophobia or other mental illness;

          -  conditions that other researchers considered inappropriate for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi Yang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuejuan Wang, MD</last_name>
    <phone>86 010 88196363</phone>
    <email>xuejuan_wang@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xuejuan Wang, MD</last_name>
      <phone>86 10-88196363</phone>
      <email>xuejuan_wang@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 26, 2020</last_update_submitted>
  <last_update_submitted_qc>April 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Xuejuan Wang,MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>FAPI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

